glp-1 pancreatitis risk New data links agonists for weight loss with higher for pancreatitis, GI events Mounjaro Pancreatitis 2026: 0.3% Risk

According to primary trials in T2DM, tirzepatide significantly reduces clinical outcomes like body weight, glycated hemoglobin (HbA1c), lipid profiles, and glucose-adjusted glucagon secretion compared to typical glucagon-like peptide1 receptor agonists (GLP1RAs) [1, 2]

doi: 10.1091/mbc.E17-06-0418 119 SiLWangXGuoJ

[18] This transcription factor functions similarly to SLIM1, in which under sulfur-limiting conditions it activates genes responsible for sulfur uptake

[2] [3] GLP-1 receptor agonists primarily work by mimicking the incretin hormone GLP-1, which enhances insulin secretion, suppresses glucagon release, slows gastric emptying, and reduces appetite

Cardiovascular outcome trials show these drugs reduce major adverse cardiovascular events rather than increase thrombotic risk